Patient-Reported Outcomes in a Cross-Section of Patients Receiving Imbruvica for Chronic Lymphocytic Leukemia and Mantle Cell Leukemia in Integrated Delivery Network Specialty Pharmacies

    Grants and Contracts Details

    StatusFinished
    Effective start/end date12/1/1811/30/19

    Funding

    • Therigy LLC: $9,750.00